Sunovion

Sunovion, Otsuka randomize first patient for GAD Phase II/III study
Clinical Trials Arena
Thu, 04/27/23 - 10:27 am
Sunovion
Otsuka
clinicat trials
ulotaront
generalized anxiety disorder
Schizophrenia: Four major clinical trials to watch in 2023
Clinical Trials Arena
Thu, 04/13/23 - 10:08 pm
clinical trials
schizophrenia
Reviva
brilaroxazine
Newron
evenamide
Sunovion
ulotaront
Acadia Pharma
pimavanserin
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Fierce Biotech
Thu, 09/30/21 - 10:52 am
Sunovion
Otsuka
biobucks
neuropsychiatric
Drugs facing the most patent expirations this year
Drug Patent Watch
Sun, 08/1/21 - 11:46 pm
patents
Novartis
Sunovion
Allergan
Bayer
Gilead Sciences
Sunovion takes Urovant's overactive bladder med Gemtesa to primary care docs as promo partnership launches
Fierce Pharma
Tue, 07/13/21 - 10:59 am
Urovant Sciences
Gemtesa
Sunovion
overactive bladder
Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial
Pharmaceutical Business Review
Tue, 07/7/20 - 10:45 am
Sunovion
clinical trials
SEP-4199
bipolar disorder
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
Xconomy
Thu, 05/21/20 - 11:14 pm
Sunovion
FDA
Parkinson's Disease
Kynmobi
Sunovion announces acceptance by FDA of NDA for Dasotraline to treat Binge Eating Disorder
Pharmaceutical Business Review
Wed, 07/31/19 - 11:59 pm
Sunovion
FDA
dasotraline
binge eating disorder
Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia
Pharmaceutical Business Review
Tue, 05/14/19 - 09:24 am
Sunovion
PsychoGenics
breakthrough therapies
SEP-363856
schizophrenia
Sunovion Pharma Promotes Antony Loebel to President & CEO
Xconomy
Wed, 03/6/19 - 08:21 pm
Sunovion
Antony Loebel
Sunovion Receives Complete Response Letter from FDA for Parkinson’s Disease Drug
CP Wire
Thu, 01/31/19 - 10:23 am
Sunovion
Parkinson's Disease
apomorphine sublingual film
APL-130277
FDA
complete response letter
Sunovion Receives Complete Response Letter from FDA for Parkinson’s Disease Drug
Thu, 01/31/19 - 10:19 am
Sunovion
Parkinson's Disease
apomorphine sublingual film
APL-130277
2018 in review: How patient centricity led to new drugs that tackle unmet need
Pharmaforum
Mon, 12/17/18 - 09:22 am
patients
drug development
Sunovion
Sangamo
Amryt Pharma
Sunovion Receives Bad News From the FDA About ADHD Drug
CP Wire
Fri, 08/31/18 - 10:45 am
Sunovion
CRL
NDA
dasotraline
ADHD
FDA
complete response letter
Sunovion Receives Bad News From the FDA About ADHD Drug
Fri, 08/31/18 - 10:42 am
Sunovion
complete response letter
dasotraline
ADHD
Sunovion drug cuts binge eating days at higher dose
Biopharma Dive
Thu, 07/26/18 - 11:49 am
Sunovion
dasotraline
binge eating
FDA to review Sunovion’s apomorphine sublingual film for Parkinson’s disease
Drug Delivery Business News
Wed, 06/13/18 - 10:21 pm
Sunovion
FDA
Parkinson's Disease
Apomorphine
Sunovion touts pivotal Ph3 trial for Parkinson’s drug
Drug Delivery Business News
Tue, 01/30/18 - 10:45 pm
Sunovion
clinical trials
Parkinson's Disease
Apomorphine
Sunovion divests asthma, allergy tech to Covis Pharma
Drug Delivery Business News
Thu, 07/13/17 - 09:23 pm
Sunovion
asthma
Covis Pharma
Alvesco
Omnaris
Sunovion seeks FDA nod for COPD treatment – again
Drug Delivery Business News
Fri, 06/30/17 - 10:47 am
Sunovion
FDA
COPD
eFlow
drug-device combos
devices

Pages